Back to top
more

Elevance Health, Inc. (ELV)

(Real Time Quote from BATS)

$420.21 USD

420.21
189,059

+2.35 (0.56%)

Updated Nov 5, 2024 10:32 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 38% (154 out of 250)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

ELV or PGNY: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

ELV vs. PGNY: Which Stock Is the Better Value Option?

Select Medical (SEM) Shares Fall 9.6% Since Q3 Earnings Miss

by Zacks Equity Research

Select Medical (SEM) reports improved performance in the Rehabilitation Hospital unit for the third quarter.

Why Is Encompass Health (EHC) Up 7.5% Despite Q3 Earnings Miss?

by Zacks Equity Research

Encompass Health (EHC) intends to open 6-10 de novo locations and increase the bed count by 100-150 per annum, till 2026.

Teladoc (TDOC) Up 1.6% Since Q3 Earnings Beat on Higher Visits

by Zacks Equity Research

Teladoc (TDOC) projects total visits in the band of 18.4-18.6 million for 2022.

PerkinElmer (PKI) Q3 Earnings Top, Revenues Decline Y/Y

by Zacks Equity Research

PerkinElmer's (PKI) third-quarter results benefit from the solid performance of the Discover & Analytics Solutions business, which was more than offset by lower COVID-related sales.

Shockwave Medical (SWAV) Beats on Q3 Earnings & Revenues

by Zacks Equity Research

Shockwave Medical's (SWAV) third-quarter results reflect robust revenue growth and expansion in gross margin.

Why Is Community Health (CYH) Up 27.8% Despite Q3 Earnings Miss?

by Zacks Equity Research

Community Health (CYH) expects labor inflation for 2023 to be within the 3-4% range.

Cardinal Health (CAH) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

Cardinal Health's (CAH) fiscal first-quarter results benefit from the solid performance of the Pharmaceutical segment.

    Exact Sciences (EXAS) Q3 Earnings Top Estimates, Margin Falls

    by Zacks Equity Research

    Exact Sciences (EXAS) registers robust revenues from the Screening and Precision Oncology segments in Q3.

    Illumina (ILMN) Q3 Earnings Beat Estimates, '22 View Slashed

    by Zacks Equity Research

    Delays in instruments and consumables purchases, negative foreign exchange impact and consumables inventory deleveraging are expected to impede growth in the rest of 2022 for Illumina (ILMN).

      AMN Healthcare (AMN) Q3 Earnings Beat Estimates, Margins Down

      by Zacks Equity Research

      AMN Healthcare's (AMN) robust Q3 results demonstrate its segmental strength.

      Accuray's (ARAY) Q1 Earnings and Revenues Lag Estimates

      by Zacks Equity Research

      Despite solid product demand, Accuray (ARAY) reports an overall soft Q1 performance.

      Myriad Genetics (MYGN) Q3 Earnings Miss, Gross Margin Falls

      by Zacks Equity Research

      Myriad Genetics (MYGN) hereditary cancer testing volume returns to growth in the third quarter. GeneSight comes up with yet another strong performance.

      AmerisourceBergen (ABC) Q4 Earnings & Revenues Top Estimates

      by Zacks Equity Research

      AmerisourceBergen's (ABC) fiscal fourth-quarter 2022 results benefit from segmental growth.

      LHC Group's (LHCG) Q3 Earnings & Revenues Miss Estimates

      by Zacks Equity Research

      LHC Group's (LHCG) third-quarter results benefit from organic growth in hospice admissions. However, home health admissions decline organically.

      Chemed (CHE) Q3 Earnings Surpass Estimates, EPS View Up

      by Zacks Equity Research

      Chemed's (CHE) full-year VITAS revenues, prior to Medicare Cap, are once again estimated to decline.

      Inari Medical (NARI) Q3 Earnings Beat, Revenues Rise Y/Y

      by Zacks Equity Research

      Inari Medical's (NARI) third-quarter results benefit from significant progress made across all its growth drivers.

      Inogen (INGN) Q3 Earnings and Revenues Beat Estimates

      by Zacks Equity Research

      Inogen's (INGN) third-quarter results benefit from higher revenues in its domestic business-to-business sales channel.

      Glaukos (GKOS) Beats on Q3 Earnings, Tightens Sales View

      by Zacks Equity Research

      Glaukos' (GKOS) Q3 revenues fall year over year but beat estimates. Lower revenues along with higher expenses hurt margins.

      Nevro (NVRO) Q3 Earnings Beat Estimates, 2022 View Revised

      by Zacks Equity Research

      Nevro's (NVRO) worldwide revenues improved on a year-over-year basis in Q3, partly owing to robust domestic performance.

      QuidelOrtho (QDEL) Q3 Earnings Top Estimates, 2022 View Revised

      by Zacks Equity Research

      QuidelOrtho's (QDEL) robust results in POC and Donor Screening product lines drives its third-quarter 2022 top line.

      Charles River (CRL) Q3 Earnings Top Estimates, Margins Dip

      by Zacks Equity Research

      Headwinds associated with foreign exchange due to the strengthening of the U.S. dollar and interest expense due to a rising interest rate environment increase concerns for Charles River (CRL).

      Zimmer Biomet (ZBH) Q3 Earnings Beat, Gross Margin Falls

      by Zacks Equity Research

      Each of Zimmer Biomet's (ZBH) geographic segments and product divisions barring S.E.T. and "Other" record year-over-year sales growth at CER.

      CVS Health (CVS) Q3 Earnings Surpass Estimates, View Up

      by Zacks Equity Research

      Robust sales growth across all three operating segments drive CVS Health's (CVS) top line.

      Hologic (HOLX) Q4 Earnings Beat Estimates, Margins Down

      by Zacks Equity Research

      Lower sales of COVID-19 assays and supply chain challenges drag Hologic's (HOLX) top line down.